CXCL1 and pancreatic ductal adenocarcinoma: This has important implications for the recurrence of this cancer following chemotherapy with gemcitabine, where an increase is shown in the expression of CXCR2 ligands, including CXCL1, in pancreatic ductal adenocarcinoma [192] and in the metastatic site of this tumor [185].